abstract |
The present invention relates to at least one novel EPO human CDR mimetibody or specified portion or variant, including isolated nucleic acids that encode at least one CDR mimetibody or specified portion or variant, CDR mimetibody or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. |